TLX News: Telix Signs Agreement to Acquire QSAM Biosciences and Its Bone Cancer Targeting Platform - 8th Feb 2024, 9:11am

[annb0t]

MELBOURNE, Australia , Feb. 8, 2024 /PRNewswire/ --.Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces it has entered into an agreement to acquire QSAM Biosciences, Inc. (U.S. OTC: QSAM) and its lead investigational drug Samarium-153-DOTMP (153Sm-DOTMP). QSAM is a United States (U.S.) based company developing therapeutic radiopharmaceuticals for primary and metastatic bone cancer. (PRNewsfoto/Telix Pharmaceuticals Limited)

153Sm-DOTMP is a novel kit-based bone-se...

>>> Read more: Telix Signs Agreement to Acquire QSAM Biosciences and Its Bone Cancer Targeting Platform